Market Cap
$296.9M
VNDA
Vanda Pharmaceuticals Inc.
$4.57 ▼ -4.99%
Prev close $4.81Market cap$296.9M
ConsensusStrong Buy
12-mo target$11.75 (+157.1%)
▲ Bullish
Analyst conviction 8/10
Insider Selling Cluster (3 insiders)High Impact Filing (7/10)28 New Institutional Positions11 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on VNDA right now — valuation, ownership and activity at a glance.
Cap Size
Micro Cap
Analyst Consensus
Strong Buy (80%)
Inst. Holders
50 funds
Inst. Value
$250.5M
Inst. Activity
28 buys / 11 sells
Insider Activity
$0.00 buy / $1.9M sell
Insider Net $
-$1.9M
Social Sentiment
69° Warm
SEC Reports
2
Price chart 30d -17.4%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Dec 12, 2026 fda_pdufa
Jul 29, 2026 SEC PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indicati
Vanda Pharmaceuticals reported Q1 2026 EPS of -$0.82, a 39.6% miss vs consensus of -$0.59, with revenue of $61.9M. The e
PRESS-RELEASE — Impact 7/10
Jun 30, 2026 Inst.
MARSHALL WACE, LLP — DOUBLED
1,225,996 shares ($7.5M)
Jun 30, 2026 Inst.
NORTHERN TRUST CORP — ADD
600,619 shares ($3.7M)
Jun 4, 2026 Insider
Mitchell Stephen Ray was granted 41,600 shares
Director
Jun 4, 2026 Insider
Honore Tage was granted 41,600 shares
Director
Jun 4, 2026 Insider
May 6, 2026 SEC Ward Anne Sempowski was granted 41,600 shares
Director
Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed
8-K — Impact 6/10
Analyst ratings buy % +0.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
80% rate it Buy or better · 10 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Sep 23, 2026 | Oppenheimer | INITIATE | Outperform | 52% |
| Aug 10, 2026 | B. Riley Securities | REITERATE | Buy | 54% |
| Aug 10, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| May 11, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Aug 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jul 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Jun 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| May 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Apr 1, 2026 | 2 | 7 | 2 | 0 | 0 | 82% | |
| Mar 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% | |
| Feb 1, 2026 | 2 | 6 | 2 | 0 | 0 | 80% |
Price targets
Where 5 covering analysts think VNDA trades over the next 12 months.
$11.75 +157.1% upside Strong Buy
Current$4.57 Low$5.75 Median$11.00 High$20.00 5 analysts
$5.75$20.00
Analyst rating Strong Buy· 1.4/5 as of Oct 2, 2026
Social media sentiment mood +6.7%
Retail-investor mood aggregated across social media. 0° = very bearish, 100° = very bullish.
69°
Warm
BearishNeutralBullish
Recent posts
IF YOU ARE SUFFERING FROM MOOD SWINGS , HERE'S A GOOD PHARMA FOR YOU (VANDA)
▲ 1 · 💬 1· ⚡ 0.0
Why I'll be buying VNDA on Monday morning
▲ 25 · 💬 30· ⚡ 0.7
Why I’ll be buying VNDA on Monday
▲ 1 · 💬 1· ⚡ 0.0
Why I’ll be buying VNDA on Monday
▲ 1 · 💬 1· ⚡ 0.0
$VNDA - Why it will be a big mover starting Monday PM
▲ 29 · 💬 24· ⚡ 0.7
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
2 SEC filing reports analyzed · 0 bullish, 1 bearish, 1 mixed, 0 neutral · avg impact 6.5/10.
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Dec 12, 2026
fda_pdufa
PDUFA: VNDA — imsidolimab in Generalized Pustular Psoriasis — 2026-12-12
FDA target action date 2026-12-12 for VNDA (Vanda Pharmaceuticals Inc.). Drug: imsidolimab. Indication: Generalized Pustular Psoriasis. PDUFA target a
Oct 2, 2026
routine
Vanda Pharmaceuticals Announces Presentation at 2026 EADV Annual Meeting
WASHINGTON, Oct. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) today announced participation at the European Academy of Dermatolog
Sep 30, 2026
short_volume
Short Volume: VNDA — 57.8% short (0.7M / 1.3M)
Short: 729,668 | Exempt: 25,059 | TRF Vol: 1,263,417 | Short Ratio: 57.8% | Off-exchange volume (dark pool + OTC)
Sep 24, 2026
Clinical Trial
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
Phase Phase 3 — COMPLETED
Sep 2, 2026
other
Vanda Pharmaceuticals Announces Participation at September 2026 Investor Conferences
WASHINGTON, Sept. 2, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate at the f
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $-0.68 | $-0.83–$-0.58 | -79.5% | -1.0% | 0↑ 4↓ | $0.1B | 5 |
| Next Q | $-0.49 | $-0.63–$-0.23 | 79.3% | -0.8% | 1↑ 3↓ | $0.1B | 5 |
| Current FY | $-3.03 | $-3.08–$-2.92 | 19.0% | -0.4% | 0↑ 4↓ | $0.2B | 5 |
| Next FY | $-0.96 | $-1.38–$-0.67 | 68.4% | +7.0% | 1↑ 3↓ | $0.3B | 5 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $-0.682 | — |
| 7d ago | $-0.675 | -0.007 |
| 30d ago | $-0.675 | -0.007 |
| 60d ago | $-0.507 | -0.175 |
| 90d ago | $-0.507 | -0.175 |
Institutional ownership
Which big funds own VNDA (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $250.5M total value (40,941,511 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, AQR. Net buying activity: 28 institutions added/increased vs 11 reduced.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 7,653,737 | $46.8M | 18.7% | — |
| STATE STREET CORP | 3,516,405 | $21.5M | 8.6% | DOUBLED +138.7% |
| AQR CAPITAL MANAGEMENT LLC | 3,497,695 | $21.4M | 8.5% | DOUBLED +155.8% |
| RENAISSANCE TECHNOLOGIES LLC | 3,441,361 | $21.1M | 8.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 2,524,040 | $15.4M | 6.2% | — |
| DIMENSIONAL FUND ADVISORS LP | 1,727,349 | $10.6M | 4.2% | — |
| MILLENNIUM MANAGEMENT LLC | 1,602,813 | $9.8M | 3.9% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 1,483,787 | $9.1M | 3.6% | — |
| TWO SIGMA INVESTMENTS, LP | 1,349,072 | $8.3M | 3.3% | — |
| MARSHALL WACE, LLP | 1,225,996 | $7.5M | 3.0% | DOUBLED +105.7% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| MARSHALL WACE, LLP | DOUBLED | 596,002 | 1,225,996 | +105.7% | $7.5M |
| NORTHERN TRUST CORP | ADD | 450,981 | 600,619 | +33.2% | $3.7M |
| Jump Financial, LLC | ADD | 198,867 | 339,907 | +70.9% | $2.1M |
| Point72 Asset Management, L.P. | ADD | 161,596 | 311,362 | +92.7% | $1.9M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | DOUBLED | 29,906 | 303,101 | +913.5% | $1.9M |
| IEQ CAPITAL, LLC | ADD | 158,070 | 282,779 | +78.9% | $1.7M |
| Connor, Clark & Lunn Investment Management Ltd. | TRIM | 376,858 | 215,206 | -42.9% | $1.3M |
| Mariner, LLC | DOUBLED | 79,854 | 173,480 | +117.2% | $1.1M |
| Man Group plc | ADD | 80,060 | 153,557 | +91.8% | $939.8K |
| MERCER GLOBAL ADVISORS INC /ADV | ADD | 65,789 | 122,546 | +86.3% | $750.0K |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
9 insiders, 12 transactions. Net -$1.9M — $0.00 bought, $1.9M sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 4, 2026 | Mitchell Stephen Ray | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Honore Tage | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Ward Anne Sempowski | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Duncan Charles Cliff | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | Chrousos Phaedra | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | DUGAN RICHARD W | Director | AWARD | 41,600 | — | — |
| Jun 4, 2026 | McGuire Daniel Patrick | SVP, GC and Secretary | AWARD | 80,000 | — | — |
| May 18, 2026 | Mitchell Stephen Ray | Director | GIFT | 25,836 | — | — |
| Apr 22, 2026 | Duncan Charles Cliff | Director | AWARD | 57,101 | — | — |
| Mar 2, 2026 | Polymeropoulos Mihael Hristos | President and CEO | SELL | 156,235 | $8.17 | $1.3M |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for VNDA.
Shares short
8,495,290
Settlement Sep 15, 2026
Change vs prior
+10.5%
Semi-monthly cycle
Days to cover
12.1
At avg daily volume
Of shares outstanding
≈14.1%
Estimate — not % of float
All VNDA filing & press-release reports (2)
- PRESS-RELEASE reportJul 29, 2026
- 8-K reportMay 6, 2026